Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Donor Lymphocyte Infusion Early Post-Transplant for High-Risk Hematologic Malignancies
NCT05327023Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2022
- Primary completion
- Jul 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of donor lymphocyte infusion in hematologic malignancy (5 arms), sponsored by National Cancer Institute. Primary endpoint: Maximally Tolerated Dose at 60 days. Started May 2022; status: recruiting.
02
Drugs
donor lymphocyte infusion
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT05327023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327023.